Korro Bio, Inc. (NASDAQ:KRRO – Free Report) – Investment analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Korro Bio in a research note issued on Tuesday, May 19th. HC Wainwright analyst M. Kapoor expects that the company will earn ($1.54) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($5.63) per share. HC Wainwright also issued estimates for Korro Bio’s Q2 2027 earnings at ($1.51) EPS, Q3 2027 earnings at ($1.55) EPS, Q4 2027 earnings at ($1.62) EPS and FY2027 earnings at ($6.23) EPS.
Korro Bio (NASDAQ:KRRO – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Korro Bio had a negative return on equity of 117.86% and a negative net margin of 1,834.48%.
Read Our Latest Analysis on KRRO
Korro Bio Price Performance
NASDAQ KRRO opened at $9.15 on Wednesday. The company’s 50 day simple moving average is $12.31 and its 200 day simple moving average is $12.05. Korro Bio has a 12 month low of $5.20 and a 12 month high of $55.89. The company has a market capitalization of $131.87 million, a P/E ratio of -0.78 and a beta of 3.07.
Insider Buying and Selling at Korro Bio
In related news, major shareholder Forest Baskett purchased 207,100 shares of the stock in a transaction on Tuesday, March 10th. The shares were bought at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the completion of the acquisition, the insider directly owned 1,297,893 shares in the company, valued at approximately $14,419,591.23. This trade represents a 18.99% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Paul Edward Walker acquired 207,100 shares of Korro Bio stock in a transaction dated Tuesday, March 10th. The stock was purchased at an average price of $11.11 per share, with a total value of $2,300,881.00. Following the completion of the purchase, the insider directly owned 1,297,893 shares of the company’s stock, valued at $14,419,591.23. The trade was a 18.99% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 1,657,320 shares of company stock worth $18,412,560 in the last 90 days. Company insiders own 4.80% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. acquired a new position in Korro Bio during the 3rd quarter worth $39,000. Wells Fargo & Company MN increased its stake in shares of Korro Bio by 45.5% in the fourth quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock worth $60,000 after purchasing an additional 2,352 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Korro Bio by 15.2% in the first quarter. Bank of New York Mellon Corp now owns 21,730 shares of the company’s stock worth $246,000 after purchasing an additional 2,875 shares during the period. PNC Financial Services Group Inc. acquired a new position in shares of Korro Bio during the 3rd quarter worth about $140,000. Finally, Millennium Management LLC boosted its stake in Korro Bio by 1.8% during the 3rd quarter. Millennium Management LLC now owns 260,333 shares of the company’s stock valued at $12,467,000 after purchasing an additional 4,650 shares during the period. Institutional investors own 13.18% of the company’s stock.
About Korro Bio
Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.
The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.
Featured Stories
- Five stocks we like better than Korro Bio
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.
